Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.
Kumar Sankhala, MD
Advertisement
Articles by Kumar Sankhala, MD
Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.
Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.
Advertisement
Latest Updated Articles
Dr. Sankhala on the TRC105/Pazopanib Combination in AngiosarcomaNovember 12th 2016
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5